Heart Failure Prevalence Rates Have Risen

The Heart Failure Society of America reports that one in four U.S. adults is expected to develop heart failure.

Updated on Oct. 5, 2026 in Heart Disease

Bold flat-color editorial illustration of a simplified anatomical heart, representing the prevalence of cardiac health issues in the United States. — A new report from the Heart Failure Society of America warns that one in four U.S. adults is projected to develop heart failure in their lifetime. AI Illustration. Upload story photo >

Live Poll

Do you feel the healthcare system is effectively delivering the latest life-saving treatments to patients?

A new report from the Heart Failure Society of America details a surge in heart failure prevalence and mortality across the country. Current projections indicate that one in four U.S. adults will develop the condition in their lifetime.

Why it matters

Rising rates are driven by an aging population and increasing cardiometabolic risk factors including obesity, hypertension, and diabetes. The report highlights an urgent need for better management, as annual costs are expected to triple by 2050.

Age-adjusted mortality rates rose 37% between 2001 and 2023, with mortality for adults aged 25 to 64 increasing significantly. Annual healthcare costs are currently $312 billion and are projected to reach $858 billion by 2050.

The players

Heart Failure Society of America

This is a professional organization dedicated to the prevention and treatment of heart failure through research and education.

The details

Researchers found that only 18% of patients with reduced ejection fraction currently utilize quadruple guideline-directed medical therapy. This treatment regimen includes a beta-blocker, renin-angiotensin system inhibitor, mineralocorticoid receptor antagonist, and SGLT2 inhibitor.

Age-adjusted mortality rates rose 37% between 2001 and 2023.
Heart failure represented 14.6% of all-cause deaths in 2023.
Early data suggest heart failure mortality is rising as of 2024.
Prevalence is expected to reach 3.8% of the U.S. population by 2050.

Health Landscape

The report highlights a growing gap between clinical guidelines and actual patient care as chronic disease burdens shift. This trajectory challenges the efficacy of population-level health initiatives like the Affordable Care Act's preventive care mandates in curbing cardiometabolic illness.

Patients should discuss guideline-directed medical therapy with their physicians to ensure they are on the most effective treatment regimen. Early management of risk factors like obesity and hypertension is essential to reducing personal lifetime risk.

The takeaway

Proactive management of cardiometabolic health is critical for preventing the development of heart failure. Implementing full guideline-directed medical therapy remains a primary opportunity to improve patient survival outcomes.